News from skylinedx A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

02 Sep, 2019, 20:00 BST Dutch Company Receives €20 Million for Skin Cancer Diagnostic Test

Benelux' largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in...


26 Jun, 2019, 12:48 BST Dutch Scale-up SkylineDx Secures Respected CAP/CLIA Certification for US Laboratory

The Rotterdam headquartered diagnostics company has been granted CAP (College of American Pathologists) accreditation, following its CLIA (Clinical...


31 Jan, 2018, 08:04 GMT SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma

SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making...


05 Dec, 2017, 14:00 GMT SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler™ with SKY92 in Multiple Myeloma

SkylineDx today announced the presentation of new data at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH) in...


13 Nov, 2017, 15:31 GMT SKY92 Gene Signature Facilitates Cost-effective, Risk-stratified Treatment of Multiple Myeloma

SkylineDx announced new data from the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)...


12 Oct, 2017, 09:05 BST SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial

SkylineDx today announced that The Institute of Cancer Research, London (ICR) and University of Leeds will use MMprofiler™ with SKY92, SkylineDx's...


25 Jul, 2017, 14:00 BST SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma (MM)

SkylineDx today announced the publication of new data that validate the Company's SKY92 gene expression signature as a prognostic tool to evaluate...


20 Jun, 2017, 14:05 BST Data Presentations at European Hematology Association (EHA) 22nd Annual Congress Further Validate SkylineDx Prognostic Tools in Multiple Myeloma

kylineDx today announced the presentation of new data that validate the use of MMprofiler with SKY92, the company's prognostic tool to risk stratify...


10 Apr, 2017, 08:30 BST SkylineDx Presented New Algorithm Demonstrating Ability to Successfully Identify Gene Sets that are Informative of Cancer Treatment Specific Survival

SkylineDx announced that they had developed TOPSPIN (Treatment Outcome Prediction using Similarity between PatIeNts) algorithm for identifying...


29 Nov, 2016, 15:48 GMT SkylineDx Announces Multiple Studies Being Presented at the 58th Annual ASH Meeting Reinforcing Utility of MMprofiler™ Gene-Based Prognostic Signature to Impact Treatment of Patients with Multiple Myeloma

SkylineDx today announced the presentation of new data that demonstrate the prognostic value of MMprofiler™ SKY92 gene signature, a gene expression...


11 Oct, 2016, 16:12 BST SkylineDx Receives Notice of Allowance to Grant Patent for Prognostic SKY92 Gene Signature in Japan

SkylineDx is pleased to announce that it has received a notice of allowance for a Japanese patent related to its prognostic SKY92 gene signature for...


05 Oct, 2016, 08:00 BST SkylineDx and Consortium of Leading European Partners awarded multi-million Euro Horizon2020 grant from European Commission

SkylineDx today announced it has been awarded a multi-million euro Horizon2020 grant from the European Commission to develop a new, and novel...


31 May, 2016, 14:00 BST SkylineDx to Present New Data Demonstrating MMprofiler™ as Robust Prognostic Tool in Multiple Myeloma at the European Hematology Association 21st Annual Congress (EHA)

SkylineDx today announced the presentation of four posters that reconfirm the prognostic value of MMprofiler™ with SKY92, the only gene-based...


08 Mar, 2016, 14:00 GMT SkylineDx Supports Myeloma Awareness Month to Raise Awareness of a Serious and Difficult to Treat Disease

SkylineDx today announces its support for Myeloma Awareness Month, an effort conducted throughout the month of March by the International Myeloma...


01 Dec, 2015, 14:00 GMT SkylineDx to Present New Data Demonstrating Prognostic Value of MMprofiler™ in Multiple Myeloma at American Society of Hematology Annual Meeting

SkylineDx today announced the presentation of two posters that demonstrate the prognostic value of the MMprofiler™, SkylineDx's gene expression...


25 Nov, 2015, 14:00 GMT SkylineDx Receives CE-IVD Mark for MMprofiler™ -- Its Innovative Gene Signature-Based Test for Multiple Myeloma

SkylineDx, today announced they have received CE-IVD registration from the European Competent Authority (Ministry of Health) for the MMprofiler™, the ...